Moderna (MRNA) 在夜盘交易中大幅上涨6.31%，引起了市场的广泛关注。
消息面上，公司近日公布了mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗耐受性良好，并在所有剂量组中均诱导出了强劲的抗体反应，验证了其mRNA平台应对多种病毒疾病的能力。此外，公司公布的一季度营收达到3.89亿美元，远超分析师预期的2.28亿美元。与此同时，其mRNA个性化肿瘤治疗性疫苗EVM16的首次人体数据也表现积极，瑞银因此上调了目标价。多重利好因素共振，共同推动了股价的强势表现。
这些积极的临床数据和财务表现，进一步增强了市场对Moderna在mRNA技术领域领先地位及其未来增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.